

THIS IS A PUBLIC ANNOUNCEMENT FOR INFORMATION PURPOSES ONLY AND IS NOT A PROSPECTUS ANNOUNCEMENT AND DOES NOT CONSTITUTE AN INVITATION OR OFFER TO ACQUIRE, PURCHASE OR SUBSCRIBE TO SECURITIES. NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION DIRECTLY OR INDIRECTLY OUTSIDE INDIA.

PUBLIC ANNOUNCEMENT



(Please scan this QR Code to view the Draft Red Herring Prospectus)

REDNEX PHARMACEUTICALS LIMITED

Our Company was originally incorporated as a Private Limited Company under the name "Rednex Pharmaceuticals Private Limited" on December 29, 2020 under the provisions of the Companies Act, 2013 with the Registrar of Companies, Ahmedabad bearing CIN: U24304GJ2020PTC119176. Subsequently, our Company was converted into a Public Limited Company vide Special Resolution passed by the Shareholders at the Extraordinary General Meeting, held on December 30, 2024 and consequently, the name of our Company was changed from "Rednex Pharmaceuticals Private Limited" to "Rednex Pharmaceuticals Limited" vide a fresh certificate of incorporation dated January 21, 2025 issued by the Registrar of Companies, Central Processing Centre bearing CIN: U24304GJ2020PLC119176. For further details of Incorporation, change of registered office of our Company, please refer to chapter titled "**History and Corporate Structure**" beginning on page 146 of the Draft Red Herring Prospectus.

Registered Office: Survey No. 586 and 231, Near SKF Bearing, Bavla Bagodara N.H 8A, Kerala, Taluka: Bavla, Ahmedabad, Gujarat, India, 382220.
Tel. No.: +91-83201-31437, E-mail: info@rednexpharma.com ; Website: https://rednexpharma.com/
Contact Person: Rima Amitbhai Dalal Company Secretary & Compliance Officer
CIN: U24304GJ2020PLC119176

OUR PROMOTERS: CHETAN RUGNATHBHAI MATHOLIYA, JAYESHKUMAR AMARSHIBHAI SABAVA AND AKASHBHAI MANSUKHBHAI GANGADIYA

"THE ISSUE IS BEING MADE IN ACCORDANCE WITH CHAPTER IX OF THE SEBI ICDR REGULATIONS (IPO OF SMALL AND MEDIUM ENTERPRISES) AND THE EQUITY SHARES ARE PROPOSED TO BE LISTED ON SME PLATFORM OF BSE ("BSE SME")."

THE ISSUE

INITIAL PUBLIC OFFER OF UPTO 27,36,000 EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH (THE "EQUITY SHARES") OF REDNEX PHARMACEUTICALS LIMITED ("OUR COMPANY" OR "THE ISSUER") AT AN ISSUE PRICE OF ₹ [●] PER EQUITY SHARE FOR CASH, AGGREGATING UP TO ₹[●] LAKHS ("PUBLIC ISSUE") OUT OF WHICH [●] EQUITY SHARES OF FACE VALUE OF ₹ 10 EACH, AT AN ISSUE PRICE OF ₹ [●] PER EQUITY SHARE FOR CASH, AGGREGATING ₹ [●] LAKHS WILL BE RESERVED FOR SUBSCRIPTION BY THE MARKET MAKER TO THE ISSUE (THE "MARKET MAKER RESERVATION PORTION"). THE PUBLIC ISSUE LESS MARKET MAKER RESERVATION PORTION I.E. ISSUE OF [●] EQUITY SHARES OF FACE VALUE OF ₹ 10 EACH, AT AN ISSUE PRICE OF ₹ [●] PER EQUITY SHARE FOR CASH, AGGREGATING UPTO ₹[●] LAKHS IS HEREIN AFTER REFERRED TO AS THE "NET ISSUE". THE PUBLIC ISSUE AND NET ISSUE WILL CONSTITUTE 26.34% AND [●] % RESPECTIVELY OF THE POST- ISSUE PAID-UP EQUITY SHARE CAPITAL OF OUR COMPANY.

THE PRICE BAND AND THE MINIMUM BID LOT WILL BE DECIDED BY OUR COMPANY IN CONSULTATION WITH THE BRLM AND WILL BE ADVERTISED IN [●] EDITION OF [●] (A WIDELY CIRCULATED ENGLISH NATIONAL DAILY NEWSPAPER) AND [●] EDITION OF [●] (A WIDELY CIRCULATED HINDI NATIONAL DAILY NEWSPAPER, AND GUJARATI EDITION OF [●], REGIONAL NEWSPAPER (WHERE OUR REGISTERED OFFICE IS LOCATED), AT LEAST TWO WORKING DAYS PRIOR TO THE BID/ ISSUE OPENING DATE AND SHALL BE MADE AVAILABLE TO THE SME PLATFORM OF BSE LIMITED ("BSE LIMITED") FOR THE PURPOSES OF UPLOADING ON THEIR WEBSITE.

In case of any revision in the Price Band, the Bid/Issue Period shall be extended for at least three additional Working Days after such revision of the Price Band, subject to the total Bid/Issue Period not exceeding ten Working Days. In cases of force majeure, banking strike or similar unforeseen circumstances, our Company, for reasons to be recorded in writing extend the Bid/Issue Period for a minimum of one Working Day, subject to the Bid/Issue Period not exceeding ten Working Days. Any revision in the Price Band, and the revised Bid/Issue Period, if applicable, shall be widely disseminated by notification to the Stock Exchanges by issuing a press release and also by indicating the change on the website of the BRLM and at the terminals of the Members of the Syndicate and by intimation to Designated Intermediaries and Sponsor Bank.

The Issue is being made through the Book Building Process, in terms of Rule 19(2)(b)(i) of the Securities Contracts (Regulation) Rules, 1957, as amended ("SCRR") read with Regulation 253 of the SEBI ICDR Regulations, as amended, wherein not more than 50% of the Net Issue shall be allocated on a proportionate basis to Qualified Institutional Buyers ("QIBs", the "QIB Portion"), provided that our Company may, in consultation with the Book Running Lead Managers, allocate up to 60% of the QIB Portion to Anchor Investors on a discretionary basis in accordance with the SEBI ICDR Regulations ("Anchor Investor Portion"), of which one-third shall be reserved for domestic Mutual Funds, subject to valid Bids being received from domestic Mutual Funds at or above the Anchor Investor Allocation Price. In the event of under-subscription, or non-allocation in the Anchor Investor Portion, the balance Equity Shares shall be added to the Net QIB Portion. Further, 5% of the Net QIB Portion shall be available for allocation on a proportionate basis only to Mutual Funds, and the remainder of the Net QIB Portion shall be available for allocation on a proportionate basis to all QIBs, including Mutual Funds, subject to valid Bids being received at or above the Issue Price. However, if the aggregate demand from Mutual Funds is less than 5% of the Net QIB Portion, the balance Equity Shares available for allocation in the Mutual Fund Portion will be added to the remaining Net QIB Portion for proportionate allocation to QIBs. Further, not less than 15% of the Net Issue shall be available for allocation on a proportionate basis to Non-Institutional Bidders (of which one third of the Non-Institutional Portion shall be reserved for Bidders with an application size of more than two lots and up to such lots equivalent to not more than ₹10 lakhs and two-thirds of the Non-Institutional Portion shall be reserved for Bidders with an application size exceeding ₹ 10 lakhs) and under-subscription in either of these sub-categories of Non-Institutional Portion may be allocated to Bidders in the other subcategory of Non-Institutional Portion, subject to valid Bids being received at or above the Issue Price and not less than 35% of the Net Issue shall be available for allocation to Individual Bidders in accordance with the SEBI ICDR Regulations, subject to valid Bids being received at or above the Issue Price. All potential Bidders (except Anchor Investors) are required to mandatorily utilize the Application Supported by Blocked Amount ("ASBA") process providing details of their respective ASBA accounts, and UPI ID in case of Individual Bidders using the UPI Mechanism, if applicable, in which the corresponding Bid Amounts will be blocked by the SCBS or by the Sponsor Bank under the UPI Mechanism, as the case may be, to the extent of respective Bid Amounts. Anchor Investors are not permitted to participate in the Issue through the ASBA process. For details, see "**Issue Procedure**" beginning on page 273 of the Draft Red Herring Prospectus.

This public announcement is made in compliance with the provisions of Regulation 247(2) of the SEBI ICDR Regulations, to inform the public that our Company is proposing to undertake, subject to applicable statutory and regulatory requirements, receipt of requisite approvals, market conditions and other considerations, an initial public offer of its Equity Shares of face value of ₹ 10 each pursuant to the Issue and the Draft Red Herring Prospectus dated September 30, 2025 has been filed with the SME Platform of BSE ("BSE SME") on September 30, 2025. The Draft Red Herring Prospectus filed with BSE SME shall be made public, for comments, if any, for a period of at least 21 days from the date of filing, by hosting it on the website of BSE SME at https://www.bsesme.com/download/399519/SME_IPO%20inPrinciple/RednexpharmaceuticalsDRHP_20250930190141.pdf, on the website of the BRLM at www.hemsecurities.com and also on the website of the Company <https://rednexpharma.com/>. Our Company invites the public to give comments on the Draft Red Herring Prospectus filed with BSE SME with respect to disclosures made in the Draft Red Herring Prospectus. The public is requested to send a copy of the comments to the Company Secretary & Compliance Officer of our Company, and/or to the BRLM at their respective addresses mentioned below. All comments must be received by our Company and/or Company Secretary & Compliance Officer of our Company and/or to the BRLM in relation to the Issue on or before 5.00 p.m. on the 21st day from the aforementioned date of filing of the Draft Red Herring Prospectus with BSE SME.

Investments in Equity and Equity-related securities involve a degree of risk and investors should not invest any funds in this Issue unless they can afford to take the risk of losing their entire investment. Investors are advised to read the risk factors carefully before taking an investment decision in the Issue. For taking an investment decision, investors must rely on their own examination of our Company and the Issue including the risks involved. The Equity Shares issued in the Issue have not been recommended or approved by the Securities and Exchange Board of India ("SEBI"), nor does SEBI guarantee the accuracy or adequacy of the Draft Red Herring Prospectus. Specific attention of the investors is invited to the section "**Risk Factors**" beginning on page 27 of the Draft Red Herring Prospectus.

Any decision to invest in the equity shares described in the Draft Red Herring Prospectus may only be taken after a Red Herring Prospectus has been filed with the ROC and must be made solely on the basis of such Red Herring Prospectus as there may be material changes in the Red Herring Prospectus from the Draft Red Herring Prospectus. The equity shares, when offered through the Red Herring Prospectus, are proposed to be listed on the BSE Limited ("**BSE SME**"). For details of the share capital and capital structure of our Company and the names of the signatories to the Memorandum of Association and the number of shares subscribed by them of our Company, see "**Capital Structure**" beginning on page 68 of the Draft Red Herring Prospectus. The liability of the members of our Company is limited. For details of the main objects of our Company as contained in our Memorandum of Association, see "**History and Corporate Structure**" beginning on page 146 of the Draft Red Herring Prospectus.

The BRLM associated with the Issue has handled 69 Public Issues in the past three years, out of which 3 Issue was closed below the Issue/ Offer Price on listing date:

Name of BRLM	Total Issue		Issue closed below IPO Price on listing date
	Mainboard	SME	
Hem Securities Limited	2	67	3 (SME)

BOOK RUNNING LEAD MANAGER TO THE ISSUE	REGISTRAR TO THE ISSUE
<p>HEM SECURITIES LIMITED Address: 904, A Wing, Naman Midtown, Senapati Bapat Marg, Elphinstone Road, Lower Parel, Mumbai-400013, Maharashtra, India Tel. No.: +91- 22- 49060000; Email: ib@hemsecurities.com Investor Grievance Email redressal@hemsecurities.com Website: www.hemsecurities.com Contact Person: Roshni Lahoti ; SEBI Regn. No. INM000010981</p>	<p>BIGSHARE SERVICES PRIVATE LIMITED Address: Office No. S6-2, 6th floor, Pinnacle Business Park, Next to Ahura Centre, Mahakali Caves Road, Andheri East, Mumbai- 400093, Maharashtra, India Telephone: +91 022-6263 8200 ; Email: ipo@bigshareonline.com Investor Grievance Email: investor@bigshareonline.com Website: www.bigshareonline.com Contact Person: Mr. Babu Rapheal C. SEBI Registration Number: INR000001385 ; CIN: U99999MH1994PTC076534</p>

COMPANY SECRETARY & COMPLIANCE OFFICER

REDNEX PHARMACEUTICALS LIMITED
Rima Amitbhai Dalal

Registered Office: Survey No. 586 and 231, Near SKF Bearing, Bavla Bagodara N.H 8A, Kerala, Taluka: Bavla, Ahmedabad, Gujarat, India, 382220.
E-mail: cs@rednexpharma.com, **Tel.:** +91- 83201-31437, **Website:** https://rednexpharma.com/

All capitalized terms used herein and not specifically defined shall have the same meaning as ascribed to them in the Draft Red Herring Prospectus.

REDNEX PHARMACEUTICALS LIMITED
On behalf of the Board of Directors

Sd/-
Rima Amitbhai Dalal
Company Secretary and Compliance Officer

Place: Ahmedabad, Gujarat
Date: October 01, 2025

Disclaimer: Rednex Pharmaceuticals Limited is proposing, subject to applicable statutory and regulatory requirements, receipt of requisite approvals, market conditions and other considerations, to make an initial public offer of its Equity Shares and has filed the Draft Red Herring Prospectus on September 30, 2025. The Draft Red Herring Prospectus is available on the website of BSE SME at https://www.bsesme.com/download/399519/SME_IPO%20inPrinciple/RednexpharmaceuticalsDRHP_20250930190141.pdf and is available on the websites of the BRLM at www.hemsecurities.com and also on the website of the Company <https://rednexpharma.com/>. Any potential investors should note that investment in equity shares involves a high degree of risk and for details relating to the same, see the section titled "**Risk Factors**" beginning on page 27 of the Draft Red Herring Prospectus. Potential investors should not rely on the Draft Red Herring Prospectus for making any investment decision. The Equity Shares have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "**Securities Act**") or any state securities laws in the United States, and unless so registered, and may not be issued or sold within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in accordance with any applicable U.S. State Securities laws. The Equity Shares are being issued and sold outside the United States in "offshore transactions" in reliance on Regulation "S" under the Securities Act and the applicable laws of each jurisdiction where such issues and sales are made. There will be no public offering in the United States.

CHANGE OF NAME PUBLIC NOTICE

I, Name THULY DEVI is legally wedded spouse of No. 150812F Rank EX.PO, Name DURGA RAJ GHALE residing at B/16 HARI DARSHAN SOCITEY, MARVE ROAD, AKASHWANI, MALWANI CHURCH, MALAD (WEST), Have changed my name from THULY DEVI to Mrs. THULI DEVI GHALE and date of birth to 15-09-1966. As per Adhar card due to erroneously endorsed vide Affidavit No. 21534, dated 22-SEP-2025.

PUBLIC NOTICE

We, Centbank Financial Services Limited and Maneck Cawashan Taleyarkhan (since deceased) joint-holders of 1102 equity shares of Face Value Rs. 2 in C G Power and Industrial Solutions Limited ("the company") have lost/misplaced certificate for the said 1102 equity shares as per details given hereunder:

Folio No.	Certificate No.	Distinctive Number
0015526	000902233	368752143
		368753244

The members of public are hereby informed that we have made an application to the company for issue of the duplicate share certificate. Any person who has objection or has any adverse claim may intimate the company with valid documents within 15 days from the date of publication of this notice at its registered office at C G House, 6th Floor, Dr. Annie Besant Road, Worli, Mumbai-400 030. The company will proceed to issue duplicate certificate for the above referred equity shares if no valid objection is lodged with the company within the aforesaid period.

Name: Centbank Financial Services Limited
Address: Central Bank of India- MMO Building, 3rd Floor (East Wing), 55 M G Road, Fort, Mumbai - 400 001.
Date: 03/10/2025



PUBLIC NOTICE

This is to inform all investors that certain unknown persons under the alias **BusyBhai**, along with others have been trying to mislead the public by wrongfully claiming to be part of **Nuvama** in order to defraud them. These miscreants are operating through an unauthorized website such as algo.busybhain.com and mobile application and other devium means to give the impression that they are connected to **Nuvama**.

Please be informed that Nuvama Wealth Management Limited and/or its subsidiaries/Group Companies are in no way associated, affiliated, or connected with the said persons/platforms. We are not involved with their business operations, activities, or any representations made by them. Nuvama Wealth Management Limited and/or its subsidiaries/Group Companies never promise or offer any assured or guaranteed returns nor do we reach out to investors through any social media platform including WhatsApp.

Investors are strongly advised not to participate in or subscribe to any such unauthorized products/schemes and to remain vigilant and exercise caution by undertaking thorough due diligence while dealing with such unauthorized communications / persons / platforms impersonating Nuvama Wealth Management Limited, its subsidiaries/Group Companies, or its employees. Please be advised that any person willingly dealing with said persons/platforms in any manner whatsoever, without proper verification, shall be doing so entirely at their own risk, as to costs and consequences.

If you have any doubts or require verification, please contact us directly through our official channels or reach out to our helpdesk at 1800-102-3335 or helpdesk@nuvama.com.

For Nuvama Wealth Management Limited

IN THE DEBTS RECOVERY TRIBUNAL-II, MUMBAI
MTNL BHAVAN, 3RD FLOOR STRAND ROAD, APOLLO BANDAR,
COLABA MARKET, COLABA,
MUMBAI-400005

TRANSFER APPLICATION NO. 42 OF 2024

SUMMONS

EXH - 12

CANARA BANK

VERSUS

MANISH HARISH NAIK AND ANR

.....APPLICANT

.....DEFENDANTS

WHEREAS, OA/201/2023 was listed before Hon'ble Presiding Officer/Registrar on 27/08/2024.

WHEREAS this Hon'ble Tribunal is pleased to issue summons/notice on the said Application under section 19(4) of the Act, (OA) filed against you for recovery of debts of Rs. 11,28,847/-

Whereas the service of summons could not be effected in ordinary manner and whereas the Application for substituted service has been allowed by this Hon'ble Tribunal

In accordance with sub-section (4) of section 19 of the Act, you, the defendants are directed as under-

(i) to show cause within thirty days of the service of summons as to why relief prayed for should not be granted;

(ii) to disclose particulars of properties or assets other than properties and assets specified by the applicant under serial number 3A of the original application;

(iii) you are restrained from dealing with or disposing of secured assets or such other assets and properties disclosed under serial number 3A of the original application, pending hearing and disposal of the application for attachment of properties;

(iv) you shall not transfer by way of sale, lease or otherwise, except in the ordinary course of his business any of the assets over which security interest is created and/or other assets and properties specified or disclosed under serial number 3A of the original application without the Prior approval of the Tribunal;

(v) you shall be liable to account for the sale proceeds realised by sale of secured assets or other assets and properties in the ordinary course of business and deposit such sale Proceeds in the account maintained with the bank or financial institutions holding security interest over such assets.

(vi) You are directed to appear before this Tribunal in person or through an Advocate and file Written Statement/Say on 22/01/2026 at 11.00 a.m. and show cause as to why reliefs prayed should not be granted.

(vii) Take notice in case of default the application shall be heard and decided in your absence.

Given under my hand and the seal of this Tribunal on this 31st day of January, 2025

(Seal)

Sd/-
Registrar,
DRT-II, Mumbai

Name & address of the defendants.

1. Mr. Manish Harish Naik
(S/o Harish Laxman Naik)
C/309, Madhu Building, Amrut Nagar Chs. Ltd., Near Amrut Nagar Circle, LBS Marg, Ghatkopar West, Mumbai-400086

Also at,
202, Marathon Vasto Apt., Sector-20/C, Plot No. 76, Airoli, Navi Mumbai-400708

Also at,
Shop No. 3, Son Sargam Apt., Sector-10/A, Plot No. 101, Vashi, Navi Mumbai-400703

2. Mr. Yasser Abdus Dalvi
(S/o Abdus Shakoor Dalvi)
104, 1st Floor, Kapadia Nagar, Building No. 14, Plot No. 198, CST Road, Kuria (W), Mumbai-400070

Public Notice in Form XIII of MOFA (Rule 11(9) (e)) District Deputy Registrar, Co-operative Societies, Mumbai City (3)

Competent Authority,

U/s 5A of the Maharashtra Ownership Flats Act, 1963.

Mhada Building, Ground Floor, Room No. 69, Bandra (E), Mumbai - 400 051.

No.DDR-3/Mum./ Deemed Conveyance/Notice/3502/2025 Date: - 01/10/2025
Application u/s 11 of Maharashtra Ownership Flats
(Regulation of the Promotion of construction, Sale, Management and Transfer) Act, 1963

Public Notice

Application No. 141 of 2025

Gyandeep Co-operative Housing Society Ltd., C-1 Gulmohar Cross Road No.7, JVPD Scheme, Vile Parle West, Mumbai - 400049, Applicant. Versus. (1) Mangal Prabhat Co- Op. Hsg. Soc Ltd., CTS No.6A, Survey No.287, Village-Vile Parle West-C-2, Gulmohar Cross Road No.7, JVPD Scheme, Vile Parle (West), Mumbai-400049, (2) Shri Bhanbai Nenshi Mahila Vidhyalaya Trust, Plot No 8/2B, Gulmohar Cross Road, 1, Link Road, opposite Irla Majjid, JVPD Scheme, Vile Parle (West)-400049, (3) Shandas Narayandas Arora, CTS No.6A, Survey No.287, C-1, Gulmohar Cross Road No.7, JVPD Scheme, Vile Parle (West), Mumbai-400049, (4) Arunkumar Pishorial Sethi, CTS No.6A, Survey No.287, Village-Vile Parle West, C-2, Gulmohar Cross Road No.7, JVPD Scheme, Vile Parle (West), Mumbai-400049, (5) Sunilkumar Pishorial Sethi, CTS No.6A, Survey No.287, Village-Vile Parle West, C-2, Gulmohar Cross Road No.7, JVPD Scheme, Vile Parle (West), Mumbai-400049, (6) Chairman Mumbai Housing Board, Annie Besant Road, Worli Shivaji Nagar, Worli, Mumbai 400030, (7) Hathkesh Nagar Co-Op. Hsg. Soc. Ltd., Harkisanandas Jagjivandas, 105, Mukund Mansion Vitthalbhai Patel Road, Mumbai - 400004, (8) M/s Vandana Traders, (Prop HP Gupta Family Trust), Mangal Darshan 14, Turner Road, Bandra, Mumbai 400050, (9) Shri Narsingdas N Adnani, (10) Smt. Rupvati Mohandas Tolani, (11) Brahma Kshatriya Co-op. Hsg. Soc. Ltd., Last known address at CTS No.6A, Survey No.287, Village-Vile Parle West, C-2, Gulmohar Cross Road No.7, JVPD Scheme, Vile Parle (West), Mumbai-400049, (12) Vile Parle Model CHSL, (Earlier known as Model Town CHSL) A-8, Gunjvara, Gulmohar Cross Road No.7, JVPD Scheme, Vile Parle (West), Mumbai-400049.Opponents and those, whose interests have been vested in the said property may submit their say at the time of hearing at the venue mentioned above. Failure to submit any say shall be presumed that nobody has any objection to this regard and further action will be taken accordingly.

Description of the Property :-

Claimed Area
Unilateral Deed of Conveyance of plot of land admeasuring 706.31 Sq. meters as per property card bearing Survey No. 287, CTS No. 6/A (part), of Village - Vile Parle, Taluka - Andheri in the District- Mumbai Suburbancomprising of Ground + 3 Upper floors having 12 residential Premises and 12 Commercial Premises on ground floor and 2 garage on ground floor in the building known as "Gyan Deep" belonging to Gyandeep Co-Operative Housing Society Ltd. in favour of the Applicant Society.

The hearing is fixed on 16/10/2025 at 3.00 p.m.

(Seal)

Sd/-
(Anand Katke)
District Deputy Registrar,
Co-operative Societies,
Mumbai City (3) Competent Authority,
U/s 5A of the MOFA, 1963.

मिडकैप फंड: अच्छे मूल्यांकन और दमदार आय वृद्धि की संभावनाओं के साथ करें निवेश

सर्वजित के सेन

इक्विटी बाजार की मिडकैप श्रेणी अक्सर निवेशकों का ध्यान आकर्षित करती रहती है। म्यूचुअल फंडों के संगठन एसोसिएशन ऑफ म्यूचुअल फंड्स इन इंडिया (एम्फो) के अनुसार, अगस्त 2025 के दौरान मिडकैप फंड में 5,330 करोड़ रुपये का निवेश दर्ज किया गया जो किसी एक महीने का अब तक का सर्वाधिक निवेश है।

मिरे ऐसेट इन्वेस्टमेंट मैनेजर्स (इंडिया) के वरिष्ठ फंड मैनेजर अंकित जैन ने कहा, 'पिछले 4-5 वर्षों के दौरान मिडकैप फंड में निवेश इक्विटी में शुद्ध निवेश का 8 से 9 फीसदी पर

बरकरार रहा है। अगस्त में यह करीब 11 फीसदी था। इससे स्पष्ट तौर पर पता चलता है कि इस श्रेणी में निवेशकों का भरोसा बढ़ा है और उनका नजरिया परिपक्व हुआ है जहां मध्यावधि में मजबूत आय वृद्धि की क्षमता है।' मिडकैप योजनाएं अपनी कुल निधि का कम से कम 65 फीसदी रकम उन कंपनियों में निवेश करती हैं जिनकी रैंकिंग बाजार पूंजीकरण के लिहाज से 101 से 250 के बीच है। 31 अगस्त, 2025 तक कुल 67 मिडकैप योजनाओं ने 4.44 लाख करोड़ रुपये की परिसंपत्तियों का प्रबंधन किया।

लंबी अवधि में फायदेमंद

बाजार में अनिश्चितता के दौरान काफी अधिक

निवेश अतार्किक लग सकता है, लेकिन यह निवेशकों की परिपक्वता और सोच समझकर जोखिम उठाने की इच्छा को दर्शाता है।

वृद्धि की क्षमता

अर्थव्यवस्था का विस्तार होने के साथ ही कई मिडकैप फर्म दमदार बहीखाते एवं मजबूत आय वाली बड़ी कंपनी के रूप में विकसित होती हैं। अपने क्षेत्र की कई अग्रणी कंपनियां इसी श्रेणी से आती हैं।

मूल्यांकन के साथ सहजता

बाजार में हालिया गिरावट ने मूल्यांकन को निवेश के लिए काफी बेहतर स्तर पर ला दिया है। जैन ने



कहा, 'पिछले एक साल के गिरावट के कारण मूल्यांकन काफी आकर्षक हो चुका है। वह सितंबर 2024 में प्राइस-टू-अर्निंग (पीई) के करीब 35 गुना से अब 28 गुना रह गया है जो

ऐतिहासिक औसत से करीब 15 फीसदी अधिक है। यह भविष्य में आय वृद्धि की क्षमता के लिहाज से बिल्कुल उचित है।'

उतार-चढ़ाव का जोखिम

बाजार में गिरावट के दौरान मिडकैप श्रेणी में लाजकैप के मुकाबले तेज गिरावट आती है। ध्वन ने कहा, 'इसमें गिरते बाजार में भारी गिरावट का जोखिम रहता है। ऐतिहासिक तौर पर देखा जाए तो बाजार में गिरावट के दौरान इसमें 40 से 50 फीसदी तक की गिरावट दिख सकती है। घरेलू सिस्टमेटिक इन्वेस्टमेंट प्लान (एसआईपी) में निवेश प्रवाह दमदार रहने और बेहतर स्थिरता की संभावना रहती है।

जोखिम लेने वालों के लिए उपयुक्त

मिडकैप फंड उन निवेशकों के लिए उपयुक्त हैं जिनकी जोखिम लेने की क्षमता अधिक है और जो लंबे समय के लिए निवेश करना चाहते हैं। ध्वन ने कहा, 'कम अधिक के लिए निवेश करने वालों अथवा उतार-चढ़ाव के प्रति कम सहनशीलता लोगों को मिडकैप फंड से बचना चाहिए। आदर्श तौर पर इसमें कम से कम 10 वर्षों के लिए निवेश की सलाह दी जाती है। एक खास इक्विटी पोर्टफोलियो के तहत मिडकैप में करीब 20 फीसदी आवंटन हो सकता है, जहां आक्रामक निवेशक मूल्यांकन कम होने पर 40 फीसदी तक निवेश कर सकते हैं।'

पहले से तैयार या निर्माणाधीन मकान

जरूरत और क्षमता देखने के बाद लें घर



संजीव सिन्हा

भारत में पहले से तैयार मकानों की मांग में गिरावट आई है। एनारॉक के हालिया मकान खरीदार धारणा सर्वेक्षण (होमबायर्स सेंटीमेंट सर्वे) से इसका पता चला है। इस साल की पहली छमाही में बने मकानों और नई पेशकशों की मांग अनुपात घटकर 16:29 रह गया है। यह वैश्विक महामारी वाले साल से बड़ा उलटफेर है, जब 2020 की पहली छमाही में पहले से तैयार मकानों का दबदबा था और अनुपात भी 46:18 था।

यह उलटफेर क्यों

पहले से बने मकानों की लोकप्रियता तब थी जब बाजार में छोटे, कम रकम वाले डेवलपर थे, जिनकी परियोजनाओं में देरी होती थी या पूरी नहीं हो पाती थीं। एनारॉक समूह के उपाध्यक्ष संतोष कुमार कहते हैं, 'खरीदारों ने पहले से बने मकानों को तब तक नहीं देखा कि वह देख सकें और रहने के वास्ते तुरंत चले जाएं। भले ही इसके लिए उन्हें अधिक कीमत चुकानी पड़े। कोविड के बाद प्रतिष्ठित और सूचीबद्ध डेवलपरों का बोलबाला हो गया और खरीदार भी उनकी परियोजनाओं में निवेश करने में संकोच नहीं करते हैं।'

पहले से तैयार मकानों का नफा-नुकसान

कुमार के मुताबिक, पहले से तैयार मकानों का एक बड़ा फायदा है कि आप जो देखते हैं वही आपको मिलता है। इसके अलावा, आपको जब तक मकान नहीं मिलता है तब तक आपको किराया नहीं देना पड़ता है, देरी होने के झंझट से मुक्ति मिली रहती है और आप जब चाहे उसमें रहने के लिए जा सकते हैं।

दूसरी ओर, ऐसे मकानों की कीमत आमतौर पर निर्माणाधीन मकानों के मुकाबले 15 से 20 फीसदी अधिक होता है। इसमें विकल्प भी सीमित होते हैं और इनकी कीमत भी धीरे-धीरे बढ़ती है। एक्सपीरियल्ड इंडिया के प्रेसिडेंट और कंटी हेड सैम चोपड़ा कहते हैं, 'जो लोग निश्चितता चाहते हैं उनके लिए यह सही है। मगर गुरुग्राम और पुणे जैसे तेजी से बदलते बाजार में नई पेशकश के साथ मूल्य का अंतर बढ़ रहा है।'

निर्माणाधीन मकानों का नफा-नुकसान

निर्माणाधीन मकानों की लागत कम होती है। आप धीरे-धीरे कर के भी रकम चुकाते हैं, जिससे आप पर आर्थिक बोझ नहीं पड़ता है। इसके अलावा, इसमें नए इंफ्रास्ट्रक्चर अनुपालन और स्मार्ट होम की सुविधाएं भी मिल जाती हैं। चोपड़ा

मकान खरीदने से पहले ध्यान रखें

■ अगर आपको तुरंत मकान चाहिए और आप पहले दिन से ही ईएमआई चुका सकते हैं तो पहले से बना मकान खरीद लें

■ मगर आप धीरे-धीरे रकम चुकाना चाहते हैं और मकान बनने का इंतजार कर सकते हैं तो आपको निर्माणाधीन मकानों का रुख करना चाहिए

■ बिल्डर का रिकॉर्ड, रेरा की स्थिति, बिल्डर के पास कितनी रकम है उसकी उचित जांच-पड़ताल करें

■ देरी होने की आशंका पर किराया और ईएमआई दोनों के लिए बजट बनाएं

■ जैसे-जैसे मकान बने वैसे-वैसे भुगतान करें

■ निर्माण कार्यों की निगरानी करें

■ उभरते हुए बुनियादी ढांचा केंद्रों में प्रतिस्पर्धी मूल्य वाली परियोजना चुनें

बताते हैं, 'इनकी कीमतें बढ़ने की काफी गुंजाइश रहती है। इन मकानों को वस्तु एवं सेवा कर (जीएसटी) से राहत मिलती है और अनिवासी भारतीयों को थोड़ा ज्यादा फायदा होता है क्योंकि रुपये में गिरावट आने पर उनकी डॉलर वाली आय बढ़ जाती है।'

राइज इन्फ्रावैचर्स के उपाध्यक्ष (सेल्स) मोहित गावरी कहते हैं, 'निर्माण से जुड़े भुगतान और पेशकश वाले ऑफर से ऐसे मकानों को खरीदने पर आर्थिक कठिनाइयां कम होती हैं। उन्होंने कहा कि रेरा लागू होने से अब देरी का जोखिम भी कम हो गया है। हालांकि, निर्माणाधीन संपत्तियों में कई खामियां भी होती हैं। कुमार बताते हैं, 'इनमें मकान मिलने तक किराया देना होता है। इसके अलावा, निर्माण और देरी का भी जोखिम होता है, जो आमतौर पर स्थानीय डेवलपरों के साथ ज्यादा देखने को मिलता है। साथ ही मकान में जाने में देरी होती है और जीएसटी शुल्क भी शामिल होता है। हालांकि, इसे अक्सर डेवलपर चुकाते हैं।'

कैसे करें चयन

निर्माणाधीन मकान उन खरीदारों के लिए सही है, जिनके पास पहले से रहने के लिए जगह है। जिन लोगों ने किसी भरोसेमंद डेवलपर से मकान बुक कराया है, जो बेहतर सुविधाएं चाहते हैं और जिन्हें निवेश पर अधिक रिटर्न की चाहत होती है। कुमार कहते हैं, 'पहले से बने मकान तब सही होते हैं जब संपत्ति अनुठी हो और सभी जरूरतों को पूरा करती हो। अधिक कीमत चुकाना कोई चिंता की बात नहीं है अगर आप तुरंत मकान में रहना चाहते हैं। चोपड़ा का कहना है, 'नोएडा, द्वारका एक्सप्रेसवे और हैदराबाद जैसे बुनियादी ढांचे से समृद्ध बाजार में निर्माणाधीन मकान काफी

लोकप्रिय हैं, जबकि मुंबई में कमी के कारण पहले से बने मकानों की मांग रहती है। हालांकि, जीएसटी दरों में कटौती ने लागत के अंतर को कम किया है, फिर भी पसंद शहर में आपूर्ति और आपकी आर्थिक क्षमता पर ही निर्भर करता है।'

क्या चुनें निवेशक

निवेशकों को निर्माणाधीन मकानों पर अक्सर बढ़त मिलती है। प्रमाणित वित्तीय योजनाकार और हम फौजी इनीशिएटिव के मुख्य कार्य अधिकारी संजीव गोविल ने कहा, 'निर्माणाधीन मकानों पर कीमतों का फायदा मिलता है, बुनियादी ढांचे से जुड़ी मूल्य वृद्धि का लाभ मिलता है और समय के साथ बेहतर लाभ भी मिलता है। पहले से तैयार मकान तभी सार्थक होते हैं जब आपको तुरंत किराया लेना होता है अथवा आय उत्पादक परिसंपत्तियों में विविधता लानी होती है। गावरी ने कहा कि पहले से बने मकानों में कीमतें बढ़ने की गुंजाइश कम होती है, क्योंकि मूल्यवृद्धि का अधिकांश हिस्सा पहले ही पूरा हो चुका होता है।'

ऋणधारकों के लिए सलाह

पहले से बने मकानों के मामले में खरीदारों को मूलधन और ब्याज पर कर लाभ तुरंत मिल जाता है। गोविल कहते हैं, 'निर्माणाधीन मकानों में आपको ये लाभ तब तक नहीं मिलते हैं, जब तक मकान आपको न मिल जाए। हालांकि, निर्माण पूर्व ब्याज का दावा आप बाद में भी कर सकते हैं।'

पहले से बने मकान उन ऋणधारकों के लिए सही है, जो रहने के लिहाज से तुरंत मकान लेना चाहते हैं, पहले दिन से ही ईएमआई चुका सकते हैं और कर राहत भी तुरंत लेना चाहते हैं।

THIS IS A PUBLIC ANNOUNCEMENT FOR INFORMATION PURPOSES ONLY AND IS NOT A PROSPECTUS ANNOUNCEMENT AND DOES NOT CONSTITUTE AN INVITATION OR OFFER TO ACQUIRE, PURCHASE OR SUBSCRIBE TO SECURITIES. NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION DIRECTLY OR INDIRECTLY OUTSIDE INDIA.

PUBLIC ANNOUNCEMENT



REDNEX PHARMACEUTICALS LIMITED

Our Company was originally incorporated as a Private Limited Company under the name "Rednex Pharmaceuticals Private Limited" on December 29, 2020 under the provisions of the Companies Act, 2013 with the Registrar of Companies, Ahmedabad bearing CIN: U24304GJ2020PTC119176. Subsequently, our Company was converted into a Public Limited Company vide Special Resolution passed by the Shareholders at the Extraordinary General Meeting, held on December 30, 2024 and consequently, the name of our Company was changed from "Rednex Pharmaceuticals Private Limited" to "Rednex Pharmaceuticals Limited" vide a fresh certificate of incorporation dated January 21, 2025 issued by the Registrar of Companies, Central Processing Centre bearing CIN: U24304GJ2020PLC119176. For further details of Incorporation, change of registered office of our Company, please refer to chapter titled "**History and Corporate Structure**" beginning on page 146 of the Draft Red Herring Prospectus.

Registered Office: Survey No. 586 and 231, Near SKF Bearing, Bavla Bagodara N.H 8A, Kerala, Taluka: Bavla, Ahmedabad, Gujarat, India, 382220.

Tel. No.: +91-83201-31437, E-mail: info@rednexpharma.com; Website: https://rednexpharma.com/

Contact Person: Rima Amitbhai Dalal Company Secretary & Compliance Officer

CIN: U24304GJ2020PLC119176

OUR PROMOTERS: CHETAN RUGNATHBHAI MATHOLIYA, JAYESHKUMAR AMARSHIBHAI SABAVA AND AKASHBHAI MANSUKHBHAI GANGADIYA

"THE ISSUE IS BEING MADE IN ACCORDANCE WITH CHAPTER IX OF THE SEBI ICDR REGULATIONS (IPO OF SMALL AND MEDIUM ENTERPRISES) AND THE EQUITY SHARES ARE PROPOSED TO BE LISTED ON SME PLATFORM OF BSE ("BSE SME")."

THE ISSUE

INITIAL PUBLIC OFFER OF UPTO 27,36,000 EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH (THE "EQUITY SHARES") OF REDNEX PHARMACEUTICALS LIMITED ("OUR COMPANY" OR "THE ISSUER") AT AN ISSUE PRICE OF ₹ (●) PER EQUITY SHARE FOR CASH, AGGREGATING UP TO ₹(●) LAKHS ("PUBLIC ISSUE") OUT OF WHICH (●) EQUITY SHARES OF FACE VALUE OF ₹ 10 EACH, AT AN ISSUE PRICE OF ₹ (●) PER EQUITY SHARE FOR CASH, AGGREGATING ₹ (●) LAKHS WILL BE RESERVED FOR SUBSCRIPTION BY THE MARKET MAKER TO THE ISSUE (THE "MARKET MAKER RESERVATION PORTION"). THE PUBLIC ISSUE LESS MARKET MAKER RESERVATION PORTION I.E. ISSUE OF (●) EQUITY SHARES OF FACE VALUE OF ₹ 10 EACH, AT AN ISSUE PRICE OF ₹ (●) PER EQUITY SHARE FOR CASH, AGGREGATING UPTO ₹(●) LAKHS IS HEREIN REFERRED TO AS THE "NET ISSUE". THE PUBLIC ISSUE AND NET ISSUE WILL CONSTITUTE 26.34% AND (●)% RESPECTIVELY OF THE POST-ISSUE PAID-UP EQUITY SHARE CAPITAL OF OUR COMPANY.

THE PRICE BAND AND THE MINIMUM BID LOT WILL BE DETERMINED BY OUR COMPANY IN CONSULTATION WITH THE BRLM AND WILL BE ADVERTISED IN (●) EDITION OF (●) (A WIDELY CIRCULATED ENGLISH NATIONAL DAILY NEWSPAPER) AND (●) EDITION OF (●) (A WIDELY CIRCULATED HINDI NATIONAL DAILY NEWSPAPER, AND GUJARATI EDITION OF (●), REGIONAL NEWSPAPER (WHERE OUR REGISTERED OFFICE IS LOCATED), AT LEAST TWO WORKING DAYS PRIOR TO THE BID/ISSUE OPENING DATE AND SHALL BE MADE AVAILABLE TO THE SME PLATFORM OF BSE LIMITED ("BSE LIMITED") FOR THE PURPOSES OF UPLOADING ON THEIR WEBSITE.

In case of any revision in the Price Band, the Bid/Issue Period shall be extended for at least three additional Working Days after such revision of the Price Band, subject to the total Bid/Issue Period not exceeding ten Working Days. In cases of force majeure, banking strike or similar unforeseen circumstances, our Company, for reasons to be recorded in writing extend the Bid/Issue Period for a minimum of one Working Day, subject to the Bid/Issue Period not exceeding ten Working Days. Any revision in the Price Band, and the revised Bid/Issue Period, if applicable, shall be widely disseminated by notification to the Stock Exchanges by issuing a press release and also by indicating the change on the website of the BRLM and at the terminals of the Members of the Syndicate and by intimation to Designated Intermediaries and Sponsor Bank.

The Issue is being made through the Book Building Process, in terms of Rule 19(2)(b)(i) of the Securities Contracts (Regulation) Rules, 1957, as amended ("SCRR") read with Regulation 253 of the SEBI ICDR Regulations, as amended, wherein not more than 50% of the Net Issue shall be allocated on a proportionate basis to Qualified Institutional Buyers ("QIBs", the "QIB Portion"), provided that our Company may, in consultation with the Book Running Lead Managers, allocate up to 60% of the QIB Portion to Anchor Investors on a discretionary basis in accordance with the SEBI ICDR Regulations ("Anchor Investor Portion"), of which one-third shall be reserved for domestic Mutual Funds, subject to valid Bids being received from domestic Mutual Funds at or above the Anchor Investor Allocation Price. In the event of under-subscription, or non-allocation in the Anchor Investor Portion, the balance Equity Shares shall be added to the Net QIB Portion. Further, 5% of the Net QIB Portion shall be available for allocation on a proportionate basis only to Mutual Funds, and the remainder of the Net QIB Portion shall be available for allocation on a proportionate basis to all QIBs, including Mutual Funds, subject to valid Bids being received at or above the Issue Price. However, if the aggregate demand from Mutual Funds is less than 5% of the Net QIB Portion, the balance Equity Shares available for allocation in the Mutual Fund Portion will be added to the remaining Net QIB Portion for proportionate allocation to QIBs. Further, not less than 15% of the Net Issue shall be available for allocation on a proportionate basis to Non-Institutional Bidders (of which one third of the Non-Institutional Portion shall be reserved for Bidders with an application size of more than two lots and up to such lots equivalent to not more than ₹10 lakhs and two-thirds of the Non-Institutional Portion shall be reserved for Bidders with an application size exceeding ₹ 10 lakhs) and under-subscription in either of these sub-categories of Non-Institutional Portion may be allocated to Bidders in the other subcategory of Non-Institutional Portion, subject to valid Bids being received at or above the Issue Price and not less than 35% of the Net Issue shall be available for allocation to Individual Bidders in accordance with the SEBI ICDR Regulations, subject to valid Bids being received at or above the Issue Price. All potential Bidders (except Anchor Investors) are required to mandatorily utilize the Application Supported by Blocked Amount ("ASBA") process providing details of their respective ASBA accounts, and UPI ID in case of Individual Bidders using the UPI Mechanism, if applicable, in which the corresponding Bid Amounts will be blocked by the SCSBs or by the Sponsor Bank under the UPI Mechanism, as the case may be, to the extent of respective Bid Amounts. Anchor Investors are not permitted to participate in the Issue through the ASBA process. For details, see "**Issue Procedure**" beginning on page 273 of the Draft Red Herring Prospectus.

This public announcement is made in compliance with the provisions of Regulation 247(2) of the SEBI ICDR Regulations, to inform the public that our Company is proposing to undertake, subject to applicable statutory and regulatory requirements, receipt of requisite approvals, market conditions and other considerations, an initial public offer of its Equity Shares of face value of ₹ 10 each pursuant to the Issue and the Draft Red Herring Prospectus dated September 30, 2025 has been filed with the SME Platform of BSE ("BSE SME") on September 30, 2025. The Draft Red Herring Prospectus filed with BSE SME shall be made public, for comments, if any, for a period of at least 21 days from the date of filing, by hosting it on the website of BSE SME at https://www.bseme.com/download/399519/SME_IP0%20InPrinciple/RednexpharmaceuticalsDRHP_20250930190141.pdf, on the website of the BRLM at www.hemsecurities.com and also on the website of the Company https://rednexpharma.com/. Our Company invites the public to give comments on the Draft Red Herring Prospectus filed with BSE SME with respect to disclosures made in the Draft Red Herring Prospectus. The public is requested to send a copy of the comments to the Company Secretary & Compliance Officer of our Company, and/or to the BRLM at their respective addresses mentioned below. All comments must be received by our Company and/or Company Secretary & Compliance Officer of our Company and/or to the BRLM in relation to the Issue on or before 5.00 p.m. on the 21st day from the aforementioned date of filing of the Draft Red Herring Prospectus with BSE SME.

Investments in Equity and Equity-related securities involve a degree of risk and investors should not invest any funds in this Issue unless they can afford to take the risk of losing their entire investment. Investors are advised to read the risk factors carefully before taking an investment decision in the Issue. For taking an investment decision, investors must rely on their own examination of our Company and the Issue including the risks involved. The Equity Shares issued in the Issue have not been recommended or approved by the Securities and Exchange Board of India ("SEBI"), nor does SEBI guarantee the accuracy or adequacy of the Draft Red Herring Prospectus. Specific attention of the investors is invited to the section "**Risk Factors**" beginning on page 27 of the Draft Red Herring Prospectus.

Any decision to invest in the equity shares described in the Draft Red Herring Prospectus may only be taken after a Red Herring Prospectus has been filed with the ROC and must be made solely on the basis of such Red Herring Prospectus as there may be material changes in the Draft Red Herring Prospectus from the Draft Red Herring Prospectus. The equity shares, when offered through the Red Herring Prospectus, are proposed to be listed on the BSE Limited ("BSE SME"). For details of the share capital and capital structure of our Company and the names of the signatories to the Memorandum of Association and the number of shares subscribed by them of our Company, see "**Capital Structure**" beginning on page 68 of the Draft Red Herring Prospectus. The liability of the members of our Company is limited. For details of the main objects of our Company as contained in our Memorandum of Association, see "**History and Corporate Structure**" beginning on page 146 of the Draft Red Herring Prospectus.

The BRLM associated with the Issue has handled 69 Public Issues in the past three years, out of which 3 Issue was closed below the Issue/ Offer Price on listing date:

Name of BRLM	Total Issue		Issue closed below IPO Price on listing date
	Mainboard	SME	
Hem Securities Limited	2	67	3 (SME)

BOOK RUNNING LEAD MANAGER TO THE ISSUE

REGISTRAR TO THE ISSUE

Hem Securities

Bigshare Services Pvt. Ltd.

HEM SECURITIES LIMITED

Address: 904, A Wing, Naman Midtown, Senapati Bapat Marg, Elphinstone Road, Lower Parel, Mumbai-400013, Maharashtra, India
Tel. No.: +91-22-49060000;
Email: ib@hemsecurities.com
Investor Grievance Email: redressal@hemsecurities.com
Website: www.hemsecurities.com
Contact Person: Roshni Lahoti; **SEBI Regn. No.** INM000010981

BIGSHARE SERVICES PRIVATE LIMITED

Address: Office No. S6-2, 6th floor, Pinnacle Business Park, Next to Ahura Centre, Mahakali Caves Road, Andheri East, Mumbai-400093, Maharashtra, India
Telephone: +91 022-6263 8200; **Email:** ipo@bigshareonline.com
Investor Grievance Email: investor@bigshareonline.com
Website: www.bigshareonline.com
Contact Person: Mr. Babu Raphael C.
SEBI Registration Number: INR000001385; **CIN:** U99999MH1994PTC076534

COMPANY SECRETARY & COMPLIANCE OFFICER

REDNEX PHARMACEUTICALS LIMITED

Rima Amitbhai Dalal

Registered Office: Survey No. 586 and 231, Near SKF Bearing, Bavla Bagodara N.H 8A, Kerala, Taluka: Bavla, Ahmedabad, Gujarat, India, 382220.

E-mail: cs@rednexpharma.com, Tel.: +91-83201-31437, Website: https://rednexpharma.com/

All capitalized terms used herein and not specifically defined shall have the same meaning as ascribed to them in the Draft Red Herring Prospectus.

REDNEX PHARMACEUTICALS LIMITED

On behalf of the Board of Directors

Sd/-

Rima Amitbhai Dalal

Company Secretary and Compliance Officer

Disclaimer: Rednex Pharmaceuticals Limited is proposing, subject to applicable statutory and regulatory requirements, receipt of requisite approvals, market conditions and other considerations, to make an initial public offer of its Equity Shares and has filed the Draft Red Herring Prospectus on September 30, 2025. The Draft Red Herring Prospectus is available on the website of BSE SME at https://www.bseme.com/download/399519/SME_IP0%20InPrinciple/RednexpharmaceuticalsDRHP_20250930190141.pdf and is available on the websites of the BRLM at www.hemsecurities.com and also on the website of the Company https://rednexpharma.com/. Any potential investors should note that investment in equity shares involves a high degree of risk and for details relating to the same, see the section titled "**Risk Factors**" beginning on page 27 of the Draft Red Herring Prospectus. Potential investors should not rely on the Draft Red Herring Prospectus for making any investment decision. The Equity Shares have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "**Securities Act**") or any state securities laws in the United States, and unless so registered, and may not be issued or sold within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in accordance with any applicable U.S. State Securities Laws. The Equity Shares are being issued and sold outside the United States in "offshore transactions" in reliance on Regulation "S" under the Securities Act and the applicable laws of each jurisdiction where such issues and sales are made. There will be no public offering in the United States.

ઠંડી આવતા પહેલા આ 5 વસ્તુઓ ખાવાથી વધશે તમારી રોગપ્રતિકારક શક્તિ



હાલમાં વિટામિન ઈ, ફાઈબર અને અન્ય પોષક તત્વો હોય છે, જે રોગપ્રતિકારક શક્તિને વધારે છે. દરરોજ મૂઠાંબર અથવા ખાવાથી માત્ર રોગપ્રતિકારક શક્તિમાં સુધારો થતો નથી, પરંતુ તેનાથી એનજી લેવલ પણ વધે છે. શિયાળામાં પહોળાથી અદામ ખાવાથી તેના પોષક તત્વોનો શોષણ સુધરે છે.

પાલક એ વિટામિન A, C અને K નો ઉત્તમ સ્ત્રોત છે. તે એન્ટીઓક્સિડન્ટ અને બળતરા વિરોધી ગુણોથી ભરપૂર છે. શિયાળામાં સુપ, પકાઈ અથવા સલાડના રૂપમાં પાલકનો સમાવેશ કરવાથી તમારી રોગપ્રતિકારક શક્તિને મજબૂત બનાવવામાં મદદ મળી શકે છે.

શિયાળાની ઋતુ નજીક આવી રહી છે. આ સિઝનમાં શરીરને માત્ર શારીરીક જ નહીં પરંતુ અન્ય પ્રકારના વાયરલ ઈન્ફેક્શનથી પણ બચાવવાની જરૂર છે. આ દિવસોમાં, તબીબી રોગપ્રતિકારક શક્તિ ધરાવતા લોકો જેમ કે ખાજીનો, વૃદ્ધ લોકો અને લાંબા સમયથી બીમાર લોકોનું સ્વાસ્થ્ય ખગડાવતું સૌથી વધુ જોખમ રહેલું છે.

હાલમાં ઈક્ટમિન નામનું તબીબી માટે છે, જે રોગપ્રતિકારક શક્તિ વધારવા માટે જાણીતું છે. શિયાળામાં હાલમાં મુશ્કેલી પડે છે. તમારી રોગપ્રતિકારક શક્તિમાં વધારો કરે છે. પરંતુ શરીરને ગરમ રાખવામાં પણ મદદ કરે છે. ઠંડીને અથવા શાકભાજી જેવા ખોરાકમાં હાલમાં પણ સમાવેશ કરી શકાય છે.



લીંબુ વિટામિન સીનો ઉત્તમ સ્ત્રોત છે, જે રોગપ્રતિકારક શક્તિ વધારવામાં મદદ કરે છે. આવી સ્થિતિમાં શિયાળામાં લીંબુ પાણી પીવું ખૂબ જ ફાયદાકારક છે. તે માત્ર શરીરને હાઈડ્રેટ જ રાખતું નથી, પરંતુ રોગપ્રતિકારક શક્તિને પણ મજબૂત બનાવે છે. સવારે પાણી પીવું સલામત અથવા ગરમ પાણી સાથે લીંબુ મિલું ગરમ પીવું.

આદામાં બળતરા વિરોધી અને એન્ટીઓક્સિડન્ટ ગુણ હોય છે. તેના નિયમિત સેવનથી શરીરની રોગપ્રતિકારક શક્તિ વધવા લાગે છે. તેમને તેને ચા અથવા ઉકાળાના સ્વરૂપમાં પી શકો છો. આદુનો ટુકડો ચાવવાથી પણ શિયાળામાં શારીરીક રાહત મળે છે.



પંચાતરસ




નારાયણ..
નારાયણ..
નારાયણ..

નારદજી તંબૂર વીણા વગાડતા વખાતા નારાયણ.. નારાયણ બોલતા બોલતા આકાશ માં ભમણ કરી રહ્યા હતા. ત્યાં અચાનક એનું ધ્યાન ધરા પરના સુંદર રાખ્યે બિહાર ની રહી યાત્રા જેમાં રસ્તા ની સાઈડ માં ઊભેલ લોકોના ટોળા દ્રશ્ય પાવનો ની હાંખી કાઢી વધારે હતી. બેત્રણ હેમને ની વચ્ચે નારદજી એ લાલ કવર નું કોળા ના આકાર નું તેમને જોયું. લાલ કવર એટલે ને નિરાખર જ નારદજી ને સેવ દેખેતા ના શાક અને પોરોલા ના ટેટ ની યાદ આવી જતા પૂર્ણી ના મોઢા ઠક ના દેખાતા ને સર્વ માં લઈ જઈ નહીં નહીં કહ્યું. પ્રથમ ધ્યાનમાં આશ્ચર્ય અને સુખ નજરે જોયું તો હેન્ટમ વચ્ચે બેઠેલ વ્યક્તિ એ તેમને નહું પણ બિહારનું બાવિયું હતું. સાચું કહું બિહારીએને એના જીવનમાં મસ્તી મજાક માં વિચરે બિહારી કોમીટી કરવાનું મન થાય તો એક નજર બિહારના બાવિયું તરફ નજર કરવાની જરૂર છે. હાઈક માં અન્ય પાસે મોળા ની બદલે મેળવવા માટે મહેનત કરનાર નેતાઓ વિશે વિચારું છું ને તો હાલ પ્રસાદ યાદવ જેવા ખુદા મજાક મજાક માં વિચારે ની મજાક ઉડાવતા નેતા માત્ર એક જ છે. માન્યું કે એનો પ્રાણીયો વધારે હોવાના લીધે એને સંપૂર્ણ જગત એના સિવાય ધ્યાનમાં રાખે છે. પરંતુ સંસદ માં જેમ અભિનેત્રીની મોટીની રાજ્યસભા માં એન્ટ્રી થતા ઉપસ્થિત લોકો ધાર નથી પાણી થઈ જાય છે એમજ હાલુજીની સ્વીચ માં સંસદ માં ઉપસ્થિત લોકો ઠાકા મારી મારી ને પેટ પકડીને હસતા હતા. હાલુજી ના ધારાધારા પ્રેમ ના ના લીધે એને નિવૃત્તિ થઈ લીધી ને એમ જેવી કોમીટી કરવી એ અન્ય માટે અશક્ય છે.

એક માણસ મુલ્યુ વાદ અંતમાં મારા મોઢી પસાર થઈ તો ધરનાર ના ધરનાર માં બેઠા થયા દરબારમાં અમરીશા પુરી ની જેમ ગોળ ગોળ ઊભા કરીને ધરનાર એ માણસ ની સાથે મુજબે પુછ્યું કે 'શ્રીવાલા કિત્તા આઝમી. ડો.. તીન.. ચાર.. .. માણસ એ પુછ્યો હતો ને જવાબ આપ્યો કે સરકાર લાગે છે કે ધરના ના નંબર વળી ગયા છે. અચાનક મોઢા બેઠા અચાજ ધરનાર એ માણસ ને ધમકાવવા ની યુદ્ધ માં આવતા બોલ્યા કે ધરથી વાસોલો કે જમાદા ન્યુઝ ચેનલ દેખેનું કે ચર્ચવા કરને કી આદત પર ગવા છે. બોલ કહું બોલા બીય માં. પાતા તુમકા હે કી બિહાર ને અચ સમોસા કરે આરુ કો લાલ કી ટુપટા નહીં હે અચ દોનો બેટરા સમુદાયા ઓર કોળા કિશ્રી ઘોલ શલવે કે રાજનીતી ને વ્યસ્ત છે. અગર પત્રકાર પુછે કી બેમાણ, હાલુજી રાખી જા દિન નહીં રહી છે. તે જાણ્યે મિલે રહેતે કી પાપા માં કી મારોદર્યાન જે પુનાવ કા કામ હો રહેતે છે. મનુષ્ય પુછે યે પાત સમજ નહીં આતી મી મોટીજી ધરનાર ધરનાર પર બાપા ક્રોન બંદ લીલા રહ્યા સળી ધરનાર ને એક જિ બાવો 'ગરીબ કો રાશન, ગરીબ કો કપડું, ગરીબ કો પર, ગરીબ કો દવા ઠાડુ મુક્ત મુક્ત. ગરીબ કો રોજગારી કી.. ના.. ના જરૂર નહીં કહું કી મોટી સરકાર કી સંસદાર.. સાંખીને મનુષ્ય ખડખડાટ ઠસવા લાગ્યો પણ ત્યાં અચાનક એના હાથમાં માં હકરડી પડી જતા ગમભરતો નો બોલ્યો કમા.. કમા.. કમા ધરનેર માલી માંયું છું મુલ્યુ થઈ ગઈ..

ધરનાર એ એટ હાસ્ય કહું ને બોલ્યા. ધમલોકો માં કમા, વિનતી, રાણીય નથી ચાલતી. કેમ?.. મું કેમ? નજર કર સામે પૂર્ણી ની વિષ્ય મોહિની વિરોધી માંથી રાજનીતી ના ચક્રમાં કમ્પાઈ ને ધમલોકો ની જેવ માં કે છે. વિચરતો ની બંધોમાં મુલ્યુ વાદ પોઝેટ માં પકડી ને લાવી હતી. રાણીય 'સાસ ભી કમ્પી બહુ થી સિરિયલ કેમ ' ની જેમ કરી હતી પણ ધરનાર ના દેખાતે માં આંસુ, ધન, સ્ત્રી, દાદ ગોરે લાચ રેષ્ટ વાલેઈ નથી. મનુષ્ય નું મન અંદર થી ખૂબ અકાળ્ય ગયું ને મનમાં બોલ્યો કે પૂર્ણી પર પ્રખ્યાત ન્યુઝ ચેનલો, ન્યુઝ પેપર એજન્સી નો મોહિલ કેમ ' ની જેમ કરી હતી રાજકર્મીઓનું સૂત્રું પડ્યું હતું. એ ઊંચા અચાજ રાણીય કરતા બોલ્યા કે ધરનાર, મારો પણ અચાનકીય અસુલ છે મુલ્યુ નો ધરો બાવિયું માં લઈને જનામો છું. રાજકર્મી, વિલે બોગ, બિઝનેસ મેન વગેરે ને મારા ઊંચારે ડિઝી કરવાનો હતો તો તેમને ક્યાં ગાજર ની મૂલી છો. તમારું પણ સેન્સેટિવ બહાર પાડી શકું છું મારી બાજુ નજર પત્રકાર જેવી ને કલમ કરવી ના ધરા જેવી સમજે બોલીયા તો એડે ઠા..

ધરનાર એ મનુષ્ય ની કંટાળાજનક બહાક સાંખીને ને વિચર ગુપ્ત તરફ નજર કરતા ઓર આખો કે મનુષ્ય ના પાપ પુષ્પ ની જોરબાંટ કરો. માર્કેટ હાથ માં લઈને વિચરુજીત બોલ્યા કે માણસ એ એના જીવન દરમિયાન 100 પાપ અને પુષ્પ એક સ્વૃં છે. જોરબાંટ સાંખીયા જ મનુષ્ય તો છે. જોરબાંટ સાંખીયા જ મનુષ્ય તો છે. જોરબાંટ સાંખીયા અને સેવાભાવી નેતા છે. માણસ રાતા રાતા કાંઈક કાંઈક કાંઈક બોલ્યા કે નક્કી વિચરુજીત થી વંચવા માં ભૂલ થાય છે. મારી જિંદગી લોકોની સેવામાં ખવાઈ લીધી છે સો પુષ્પ ક્યાં હશે પાપ એક જ કદાચ ધરનાર થી કહું હશે. ધરનાર એ મનુષ્ય ની એકપણ વાત સાંખીયા વગર નહીં ની યાતના ની સજ કરવાની એવી. શાશ ના નહીં ની યાતના વિશે માણસ એ વાંચ્યું હતું એટલે એના મગજ માંથી શબ્દ બહાર ઊંચા ને વાચ્યા એ મોમાં પર તાળા લગાવી દીધા હતા. સૂં કરવું કેમ છુટવું? પણ યાતના થી અચાનક માણસને ધરા પર વિરાજમાન સંજ્ઞ ની મોહી પીટિયા યાતના એટલે પદ યાતના વિશે વિચારવાનું છોડી નોમોમન નક્કી કરી કે નહીં ની સાતઠઠ વાંદીને શ્યા અપીળા ને માં સુંઘીથી માં પ્રયં સંજ્ઞતા મેલવાઈ.. બકા, તુ કારો તને નહી. અચાજાતા માણસ ની નહી. શિકાર કરે છે. ના.. રે.. ના.. માં લાખો ભેસ સાથે અજોળા ને ધરનાર પણ ટેકનોલોજી પર પૂરી થી એનું હાઈટર જેટ ધેનું જેવા બનાવે છે. આ હાઈટર ધેનું જેવા બનાવે છે. આ હાઈટર ધેનું મુશ્કેલી ના ધર માં મજાક બની પાંચમાં પકડીને ધમલોક લઈ તાકાત આગળ બેંક ના લોકર પણ કદ્યું કરી યાતના ની.. હાઈટર ધેનું મેંયું કરું વગેરે ભીતક સંપતિ સાથે માં મુંયું કરું છે એ પની, પૂન, પૂર્ણી કે અન્ય સંજ્ઞો પણ આતાં નથી. એટલા થયે હો વીઠાઈ પણ એટલા એટલે આંદર દોરો રમટ બોલ્યા ને. નાલો તો કરવો જ



THIS IS A PUBLIC ANNOUNCEMENT FOR INFORMATION PURPOSES ONLY AND IS NOT A PROSPECTUS ANNOUNCEMENT AND DOES NOT CONSTITUTE AN INVITATION OR OFFER TO ACQUIRE, PURCHASE OR SUBSCRIBE TO SECURITIES. NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION DIRECTLY OR INDIRECTLY OUTSIDE INDIA.



REDNEX PHARMACEUTICALS LIMITED

Our Company was originally incorporated as a Private Limited Company under the name "Rednex Pharmaceuticals Private Limited" on December 29, 2020 under the provisions of the Companies Act, 2013 with the Registrar of Companies, Ahmedabad bearing CIN: U24304GJ2020PLC119176. Subsequently, our Company was converted into a Public Limited Company vide Special Resolution passed by the Shareholders at the Extraordinary General Meeting, held on December 30, 2024 and consequent company name was changed from "Rednex Pharmaceuticals Private Limited" to "Rednex Pharmaceuticals Limited" vide a fresh certificate of incorporation dated January 21, 2025 issued by the Registrar of Companies, Central Processing Centre bearing CIN: U24304GJ2020PLC119176. For further details of incorporation, change of registered office of our Company, please refer to chapter titled "History and Corporate Structure" beginning on page 146 of the Draft Red Herring Prospectus.

Registered Office: Survey No. 586 and 231, Near SKF Bearing, Bavla Bagodara N.H.6A, Kerala, Taluka: Bavla, Ahmedabad, Gujarat, India, 382220.
Tel. No.: +91- 83201-31437, E-mail: info@rednexpharma.com, Website: https://rednexpharma.com
Contact Person: Rima Amithbhai Dalal, Compliance Officer & Company Secretary
CIN: U24304GJ2020PLC119176

OUR PROMOTERS: CHETAN RUGNATHBHAI MATHOLIYA, JAYESHKUMAR AMARSHIBHAI SABAVA AND AKASHBHAI MANSUKHBHAI GANGADIYA
"THE ISSUE IS BEING MADE IN ACCORDANCE WITH CHAPTER IX OF THE SEBI ICDR REGULATIONS (IPO OF SMALL AND MEDIUM ENTERPRISES) AND THE EQUITY SHARES ARE PROPOSED TO BE LISTED ON SME PLATFORM OF BSE ("BSE SME")."

THE ISSUE

INITIAL PUBLIC OFFER OF UPTO 27,36,000 EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH (THE "EQUITY SHARES") OF REDNEX PHARMACEUTICALS LIMITED ("OUR COMPANY" OR "THE ISSUE") AT AN ISSUE PRICE OF ₹ 10/- PER EQUITY SHARE FOR CASH, AGGREGATING UP TO ₹ 273.60 LAKHS ("NET ISSUE") OUT OF WHICH (A) EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH, AT AN ISSUE PRICE OF ₹ 10/- PER EQUITY SHARE FOR CASH, AGGREGATING UP TO ₹ 273.60 LAKHS ("NET ISSUE") AND (B) RESERVED FUND SUBSCRIPTION PORTION OF THE ISSUE (THE "MARKET MAKER RESERVATION PORTION") THE PUBLIC ISSUE LESS MARKET MAKER RESERVATION PORTION I.E. ISSUE OF (C) EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH, AT AN ISSUE PRICE OF ₹ 10/- PER EQUITY SHARE FOR CASH, AGGREGATING UP TO (C) LAKHS IS HEREIN REFERRED TO AS THE "NET ISSUE". THE PUBLIC ISSUE AND NET ISSUE WILL CONSTITUTE 26.34% AND (C) % RESPECTIVELY OF THE POST-ISSUE PAID-UP EQUITY SHARE CAPITAL OF OUR COMPANY. THE PRICE BAND AND THE MINIMUM BID LOT WILL BE DETERMINED BY OUR COMPANY IN CONSULTATION WITH THE BRLM AND WILL BE ADVERTISED IN (A) WIDELY CIRCULATED ENGLISH NATIONAL DAILY NEWSPAPER AND (B) EDITION OF (C) (A WIDELY CIRCULATED HINDI NATIONAL DAILY NEWSPAPER, AND GUJARATI EDITION OF (A) REGIONAL NEWSPAPER (WHERE OUR REGISTERED OFFICE IS LOCATED), AT LEAST TWO WORKING DAYS PRIOR TO THE BID/ISSUE OPENING DATE AND SHALL BE AVAILABLE UPON THE SME PLATFORM OF BSE LIMITED ("BSE LIMITED") FOR THE PURPOSES OF UPLOADING ON THEIR WEBSITE.

Platform of BSE Limited ("BSE Limited") for the purposes of uploading on their website. The issue is being made through the Book Building Process, in terms of Rule 19(2)(b)(i) of the Securities Contracts (Regulation) Rules, 1957, as amended ("SCRR") read with Regulation 253 of the SEBI ICDR Regulations, as amended, wherein not more than 50% of the Net Issue shall be allocated on a proportionate basis to Qualified Institutional Buyers ("QIBs", the "QIB Portion"), provided that our Company may, in consultation with the Book Running Lead Managers, allocate up to at least 50% of the QIB Portion to Anchor Investors on a discretionary basis in accordance with the SEBI ICDR Regulations ("Anchor Investor Portion"), of which one-third shall be reserved for domestic Mutual Funds, subject to valid bids being received from domestic Mutual Funds at or above the Anchor Investor Allocation Price. In the event of under-subscription, or non-allocation in the Anchor Investor Portion, the balance Equity Shares shall be added to the Net QIB Portion. Further, 5% of the Net QIB Portion shall be available for allocation on a proportionate basis only to Mutual Funds, and the remainder of the Net QIB Portion shall be available for allocation on a proportionate basis to all QIBs, including Mutual Funds, subject to valid bids being received at or above the Issue Price. However, if the aggregate demand from Mutual Funds is less than 5% of the Net QIB Portion, the balance Equity Shares available for allocation in the Mutual Fund QIB Portion will be added to the remaining Net QIB Portion for proportionate allocation to QIBs. Further, not less than 15% of the Net Issue shall be available for allocation on a proportionate basis to Non-Institutional Bidders of which one-third of the Non-Institutional Portion shall be reserved for Bidders with an application size of more than two lots and up to such lots equivalent to not more than ₹10 lakhs and two-thirds of the Non-Institutional Portion shall be reserved for Bidders with an application size exceeding ₹ 10 lakhs and under-subscription in either of these sub-categories of Non-Institutional Portion may be allocated to Bidders in the other subcategory of Non-Institutional Portion, subject to valid bids being received at or above the Issue Price and not less than 35% of the Net Issue shall be available for allocation to Individual Bidders in accordance with the SEBI ICDR Regulations, subject to valid bids being received at or above the Issue Price. All potential Bidders (except Anchor Investors) are required to mandatorily utilize the Application Supported by Blocked Amount ("ASBA") process providing details of their respective ASBA accounts, and UPI ID in case of Individual Bidders using the UPI Mechanism, if applicable, in which the corresponding Bid Amounts will be blocked by the SCSBs or by the Sponsor Bank under the UPI Mechanism, as the case may be, to the extent of respective Bid Amounts. Anchor Investors are not permitted to participate in the Issue through the ASBA process. For details, see "Issue Procedure" beginning on page 273 of the Draft Red Herring Prospectus.

This public announcement is made in compliance with the provisions of Regulation 24(2)(7) of the SEBI ICDR Regulations, to inform the public that our Company is proposing to undertake, subject to applicable statutory and regulatory requirements, receipt of requisite approvals, market conditions and other considerations, an initial public offer of its Equity Shares of face value of ₹ 10 each pursuant to the Issue and the Draft Red Herring Prospectus dated September 30, 2025 has been filed with the SME Platform of BSE ("BSE SME") on September 30, 2025. The Draft Red Herring Prospectus filed with BSE SME shall be made public, for comments, if any, for a period of at least 21 days from the date of filing, by hosting it on the website of BSE SME at https://www.bseindia.com/download/399519/SME_IPO%20PrincipleRednexpharmaceuticalsDRHP_20250930190141.pdf, on the website of the BRLM at www.hemsecurities.com and also on the website of the Company https://rednexpharma.com. Our Company invites the public to give comments on the Draft Red Herring Prospectus filed with BSE SME with respect to disclosures made in the Draft Red Herring Prospectus. The public is requested to send a copy of the comments to the Company Secretary & Compliance Officer of our Company and/or to the BRLM at their respective addresses mentioned below. All comments must be received by our Company and/or Company Secretary & Compliance Officer of our Company and/or to the BRLM in relation to the Issue on or before 5:00 p.m. on the 21st day from the aforementioned date of filing of the Draft Red Herring Prospectus with BSE SME.

Name of BRLM	Total Issue		Issue closed below IPO Price on listing date
	Mainboard	SME	
Hem Securities Limited	2	67	3 (SME)

BOOK RUNNING LEAD MANAGER TO THE ISSUE: REGISTRAR TO THE ISSUE

Hem Securities
BIGHARE SERVICES PVT. LTD.

REDNEX PHARMACEUTICALS LIMITED
Rima Amithbhai Dalal
Registered Office: Survey No. 586 and 231, Near SKF Bearing, Bavla Bagodara N.H.6A, Kerala, Taluka: Bavla, Ahmedabad, Gujarat, India, 382220.
E-mail: cs@rednexpharma.com, Tel.: +91- 83201-31437, Website: https://rednexpharma.com/

All capitalized terms used herein and not specifically defined shall have the same meaning as ascribed to them in the Draft Red Herring Prospectus.

Place: Ahmedabad, Gujarat
Date: October 01, 2025

Disclaimer: Rednex Pharmaceuticals Limited is proposing, subject to applicable statutory and regulatory requirements, receipt of requisite approvals, market conditions and other considerations, to issue an initial public offer of its Equity Shares and has filed the Draft Red Herring Prospectus on September 30, 2025. The Draft Red Herring Prospectus is available on the website of BSE SME at https://www.bseindia.com/download/399519/SME_IPO%20PrincipleRednexpharmaceuticalsDRHP_20250930190141.pdf and is available on the websites of the BRLM at www.hemsecurities.com and also on the website of the Company https://rednexpharma.com. All potential investors should note that investment in equity shares involves a high degree of risk and for details relating to the same, see the section titled "Risk Factors" beginning on page 27 of the Draft Red Herring Prospectus. Potential investors should not rely on the Draft Red Herring Prospectus for making any investment decision. The Equity Shares have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "Securities Act") or any state securities laws in the United States, and unless so registered, and may not be issued or sold within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in accordance with any applicable U.S. State Securities Laws. The Equity Shares are being issued and sold outside the United States in "offshore transactions" in reliance on Regulation "S" under the Securities Act and the applicable laws of each jurisdiction where such issues and sales are made. There will be no public offering in the United States.